These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 26183670)
1. Long-term survival after high-dose chemotherapy with autologous hematopoietic cell transplantation in metastatic breast cancer. Hamilton BK; Rybicki L; Abounader D; Andresen S; Kalaycio M; Sobecks R; Pohlman B; Hanna R; Dean R; Liu H; Hill B; Bolwell B; Copelan E Hematol Oncol Stem Cell Ther; 2015 Sep; 8(3):115-24. PubMed ID: 26183670 [TBL] [Abstract][Full Text] [Related]
2. Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review. Kobayashi T; Ichiba T; Sakuyama T; Arakawa Y; Nagasaki E; Aiba K; Nogi H; Kawase K; Takeyama H; Toriumi Y; Uchida K; Kobayashi M; Kanehira C; Suzuki M; Ando N; Natori K; Kuraishi Y Breast Cancer; 2012 Jul; 19(3):218-37. PubMed ID: 22532161 [TBL] [Abstract][Full Text] [Related]
3. Complete response after high-dose chemotherapy and autologous hemopoietic stem cell transplatation in metastatic breast cancer results in survival benefit. Kurian S; Qazilbash M; Fay J; Wolff S; Herzig R; Hobbs G; Bunner P; Weisenborn R; Aya-Ay M; Lynch J; Ericson S Breast J; 2006; 12(6):531-5. PubMed ID: 17238982 [TBL] [Abstract][Full Text] [Related]
4. Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry. Martino M; Ballestrero A; Zambelli A; Secondino S; Aieta M; Bengala C; Liberati AM; Zamagni C; Musso M; Aglietta M; Schiavo R; Castagna L; Rosti G; Bruno B; Pedrazzoli P Bone Marrow Transplant; 2013 Mar; 48(3):414-8. PubMed ID: 22863724 [TBL] [Abstract][Full Text] [Related]
5. High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer: a 10-year experience. Laport GF; Grad G; Grinblatt DL; Bitran JD; Williams SF Bone Marrow Transplant; 1998 Jan; 21(2):127-32. PubMed ID: 9489628 [TBL] [Abstract][Full Text] [Related]
6. A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant. Nieto Y; Cagnoni PJ; Shpall EJ; Xu X; Murphy J; Vredenburgh J; Chao NJ; Bearman SI; Jones RB Clin Cancer Res; 1999 Nov; 5(11):3425-31. PubMed ID: 10589754 [TBL] [Abstract][Full Text] [Related]
7. Characteristics associated with long-term progression-free survival following high-dose chemotherapy in metastatic breast cancer and influence of chemotherapy dose. Schneeweiss A; Hensel M; Sinn P; Khbeis T; Haas R; Bastert G; Ho AD Ann Oncol; 2002 May; 13(5):679-88. PubMed ID: 12075735 [TBL] [Abstract][Full Text] [Related]
8. [Combination of high-dose chemotherapy with autologous hematopoietic stem cell transplantation for recurrent and high-risk breast cancer: a pilot study]. Shi Y; Pan F; Han X Zhonghua Yi Xue Za Zhi; 1999 Dec; 79(12):890-3. PubMed ID: 11715500 [TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of patients with metastatic breast cancer: results of a retrospective, single-center analysis from 2000 to 2005. Geiger S; Cnossen JA; Horster S; DiGioia D; Heinemann V; Stemmler HJ Anticancer Drugs; 2011 Oct; 22(9):933-9. PubMed ID: 21666437 [TBL] [Abstract][Full Text] [Related]
10. Epirubicin-containing high-dose chemotherapy followed by autologous hematopoietic progenitor cell transfusion for patients with chemotherapy-sensitive metastatic breast cancer: results of 5-year follow-up. Ito Y; Mukaiyama T; Ogawa M; Mizunuma N; Takahashi S; Aiba K; Horikoshi N Cancer Chemother Pharmacol; 1999; 43(1):8-12. PubMed ID: 9923535 [TBL] [Abstract][Full Text] [Related]
11. High-dose busulfan and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer. Demirer T; Buckner CD; Appelbaum FR; Clift R; Storb R; Myerson D; Lilleby K; Rowley S; Bensinger WI Bone Marrow Transplant; 1996 May; 17(5):769-74. PubMed ID: 8733696 [TBL] [Abstract][Full Text] [Related]
12. Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone. Vredenburgh JJ; Coniglio D; Broadwater G; Jones RB; Ross M; Shpall EJ; Hussein A; Rizzieri D; Marks LB; Gilbert C; Affronti ML; Moore S; McDonald C; Petros WP; Peters WP Biol Blood Marrow Transplant; 2006 Feb; 12(2):195-203. PubMed ID: 16443517 [TBL] [Abstract][Full Text] [Related]
13. Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. Nieto Y; Nawaz S; Jones RB; Shpall EJ; Cagnoni PJ; McSweeney PA; Barón A; Razook C; Matthes S; Bearman SI J Clin Oncol; 2002 Feb; 20(3):707-18. PubMed ID: 11821452 [TBL] [Abstract][Full Text] [Related]
14. Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. Cao TM; Negrin RS; Stockerl-Goldstein KE; Johnston LJ; Shizuru JA; Taylor TL; Rizk NW; Wong RM; Blume KG; Hu WW Biol Blood Marrow Transplant; 2000; 6(4):387-94. PubMed ID: 10917574 [TBL] [Abstract][Full Text] [Related]
15. Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group. Koscielniak E; Klingebiel TH; Peters C; Hermann J; Burdach ST; Bender-Götze C; Müller-Weihrich ST; Treuner J Bone Marrow Transplant; 1997 Feb; 19(3):227-31. PubMed ID: 9028550 [TBL] [Abstract][Full Text] [Related]
16. High-dose alkylating agents with autologous hematopoietic stem cell support and trastuzumab in ERBB2 overexpressing metastatic breast cancer: a feasibility study. Gonçalves A; Braud AC; Viret F; Tarpin C; Charaffe-Jauffret E; Jacquemier J; Maraninchi D; Viens P Anticancer Res; 2005; 25(1B):663-7. PubMed ID: 15816643 [TBL] [Abstract][Full Text] [Related]
17. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. Stadtmauer EA; O'Neill A; Goldstein LJ; Crilley PA; Mangan KF; Ingle JN; Brodsky I; Martino S; Lazarus HM; Erban JK; Sickles C; Glick JH N Engl J Med; 2000 Apr; 342(15):1069-76. PubMed ID: 10760307 [TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation. Boudin L; Chabannon C; Sfumato P; Sabatier R; Bertucci F; Tarpin C; Provansal M; Houvenaeghel G; Lambaudie E; Tallet A; Resbeut M; Charafe-Jauffret E; Calmels B; Lemarie C; Boher JM; Extra JM; Viens P; Gonçalves A Eur J Cancer; 2016 Apr; 57():118-26. PubMed ID: 26918737 [TBL] [Abstract][Full Text] [Related]
19. High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma - a phase II study. Toh HC; McAfee SL; Sackstein R; Multani P; Cox BF; Garcia-Carbonero R; Colby C; Spitzer TR Bone Marrow Transplant; 2000 Jan; 25(1):19-24. PubMed ID: 10654009 [TBL] [Abstract][Full Text] [Related]
20. Outcomes of high-dose chemotherapy and autologous stem cell transplant in isolated locally recurrent breast cancer: a multicenter evaluation. Vij R; DiPersio J; Brown R; Trinkaus K; Abboud C; Meehan KR; Frenette G; Freytes C; Goodnough LT; Khoury H; Ponnuri J; Adkins D Bone Marrow Transplant; 2000 Nov; 26(9):947-53. PubMed ID: 11100273 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]